Related Experiment Video
Updated: May 27, 2025
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a
Roger A Barker1, Mart Saarma2, Clive N Svendsen3
1Department of Clinical Neurosciences and Cambridge Stem Cell Institute, John van Geest Centre for Brain Repair, Forvie Site, Cambridge, UK.
Abstract:
In 2023, a workshop was organized by the UK charity Cure Parkinson's with The Michael J Fox Foundation for Parkinson's Research and Parkinson's UK to review the field of growth factors (GFs) for Parkinson's disease (PD). This was a follow up to a previous meeting held in 2019.1 This 2023 workshop reviewed new relevant data that has emerged in the intervening 4 years around the development of new GFs and better models for studying them including the merit of combining treatments as well as therapies that can be modulated. We also discussed new insights into GF delivery and trial design that have emerged from the analyses of completed GDNF trials, including the patient voice, as well as the recently completed CDNF trial.2 We then concluded with our recommendations on how GF studies in PD should develop going forward.
Insights
This workshop reviewed growth factors (GFs) for Parkinson's disease (PD), discussing new data, delivery methods, and trial designs. Recommendations were made for future GF research in PD.
Area of Science:
- Neuroscience
- Regenerative Medicine
Background:
- A 2019 workshop identified growth factors (GFs) as a promising therapeutic avenue for Parkinson's disease (PD).
- Significant advancements in GF research, including new therapeutic agents and improved study models, have emerged since 2019.
Purpose of the Study:
- To review and synthesize recent developments in growth factor research for Parkinson's disease.
- To discuss novel insights into GF delivery, combination therapies, and clinical trial design for PD.
Main Methods:
- A 2023 workshop convened experts from Cure Parkinson's, The Michael J Fox Foundation, and Parkinson's UK.
- Discussions included analysis of completed GDNF and CDNF trials, incorporating patient perspectives.
- Evaluation of new data on GF development, disease models, and therapeutic modulation strategies.
Main Results:
- Identified progress in developing novel growth factors and refining disease models for PD research.
- Highlighted key learnings from GDNF and CDNF trials regarding delivery, patient experience, and trial parameters.
- Recognized the potential of combination therapies and modulated treatments for Parkinson's disease.
Conclusions:
- Growth factor research for Parkinson's disease requires continued investigation with refined approaches.
- Future studies should incorporate insights from recent trials, patient feedback, and advanced therapeutic strategies.
- Recommendations were formulated to guide the progression of growth factor studies in Parkinson's disease research.
Related Concept Videos
01:15Parkinson's Disease: Overview
01:37Neural Regulation
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...